Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Single-Center Open-label Study of C.001 in Patients With Significant Retinal Pigment Epithelium Mediated Maculopathy (RMM)

NCT07594236 is registered in ClinicalTrials.gov with Cellio Therapeutics Inc as lead sponsor.

NCT NCT07594236
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07594236 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Single-Center Open-label Study of C.001 in Patients With Significant Retinal Pigment Epithelium Mediated Maculopathy (RMM)
Lead sponsor
Cellio Therapeutics Inc
Phase
Phase 1
Overall status
Recruiting
Start date
April 7, 2026
Completion date
December 31, 2029
Enrollment
15 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

age related macular degeneration, geographic atrophy, rpe-mediated maculopathy, stargardt disease